logo-loader

BioSig Technologies appoints Brenda Castrodad to lead its Human Resources department

Published: 03:45 17 Feb 2021 AEDT

BioSig Technologies, Inc. -
Most recently, Castrodad led the HR department at TissueTech, Inc., a Miami, FL-based biotech leader in regenerative amniotic tissue-based products

BioSig Technologies, Inc. (NASDAQ:BSGM) announced Tuesday that it has appointed Brenda Castrodad to lead its Human Resources department.

The medical technology company seasoned executive noted that Castrodad brings a wealth of experience in leading organizational development in start-ups and Fortune 500 companies within the life sciences sector.  Most recently, she led the HR department at TissueTech, Inc., a Miami, FL-based biotech leader in regenerative amniotic tissue-based products, where she was responsible for transformation and automation of the company’s HR practices, talent planning, and team building.

READ: BioSig Technologies says it has entered into three new evaluation agreements for its PURE EP System

Prior to TissueTech, Inc., Castrodad spent six years at HeartWare, Inc., a heart failure medtech company acquired by Medtronic in 2016 for $1.1 billion. By optimizing the internal talent acquisition function and aligning business practices, she helped grow the organization from approximately 80 to 500-plus staff which achieved approx. $250 million in revenues before the acquisition. Earlier in her career, Castrodad spent 16 years at Schering-Plough Corp, a pharmaceutical company acquired in 2009 for $41.1 billion by Merck & Co.

"A proven champion of culture, growth, and transformation, Brenda impressed us with her experience in positioning HR as a strategic business partner to create a platform for successful talent acquisition and employee engagement. Brenda’s expertise in supporting rapid growth, combined with her knowledge of our industry, should be invaluable as we scale up our customer-facing teams while further developing the in-house talent to drive the innovation engine. We look forward to working with Brenda as we prepare the Company for commercial success,” commented Kenneth L. Londoner, chairman, and CEO of BioSig in a statement.

“It is a privilege to join the BioSig team of dedicated and experienced professionals across the organization. I’m energized by the company’s culture of innovation and commercialization plans.  I’m thrilled to be a valuable contributor to the incredible growth path ahead of us,” added Castrodad.

BioSig Technologies is commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The company’s first product, the PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Contact the author at jon.hopkins@proactiveinvestors.com

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

8 hours, 23 minutes ago